Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2025-12-26 @ 1:21 AM
Study NCT ID:
NCT03445533
Status:
TERMINATED
Last Update Posted:
2022-11-08
First Post:
2018-02-13
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Sponsor:
Idera Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-01
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-13
First Submit QC Date:
None
Study First Post Date:
2018-02-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-08-19
Results First Submit QC Date:
None
Results First Post Date:
2022-11-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-17
Last Update Post Date:
2022-11-08
Last Update Post Date Type:
ACTUAL